Holen Sie sich die Stockscreener-App
39.34
1.38%
-0.55
Handel nachbörslich:
39.56
0.22
+0.56%
Schlusskurs vom Vortag:
$39.89
Offen:
$39.9
24-Stunden-Volumen:
332.44K
Relative Volume:
0.86
Marktkapitalisierung:
$1.15B
Einnahmen:
$219.79M
Nettoeinkommen (Verlust:
$-57.47M
KGV:
-18.30
EPS:
-2.15
Netto-Cashflow:
$-19.25M
1W Leistung:
+2.08%
1M Leistung:
+2.85%
6M Leistung:
+95.53%
1J Leistung:
+20.23%
1-Tages-Spanne:
$38.67
$40.70
1-Wochen-Bereich:
$37.29
$41.34
52-Wochen-Spanne:
$14.59
$42.17
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Vergleichen Sie CSTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
39.34 | 1.16B | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Can Castle Biosciences Inc. stock continue upward trendWeekly Profit Analysis & Daily Profit Maximizing Tips - ulpravda.ru
What risks investors should watch in Castle Biosciences Inc. stock2025 Support & Resistance & AI Powered Buy/Sell Recommendations - ulpravda.ru
Why Castle Biosciences Inc. stock is considered a top pickBull Run & Weekly High Potential Alerts - ulpravda.ru
Is Castle Biosciences Inc. stock near bottom after declineRisk Management & Reliable Breakout Forecasts - ulpravda.ru
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 1,339 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 2,678 Shares of Stock - MarketBeat
Castle Biosciences Inc (FRA:086) Stock Price, Trades & News - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What drives Castle Biosciences Inc stock priceWeekly Market Snapshot & Affordable Trading Plans - Early Times
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - MSN
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares - MarketBeat
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus - Yahoo Finance
Is Castle Biosciences Inc. stock vulnerable to regulatory risksHealthcare Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
Breakouts Watch: Why Castle Biosciences Inc. stock is considered a top pick2025 Sector Review & Real-Time Volume Triggers - moha.gov.vn
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - sharewise.com
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
Castle Biosciences stock hits 52-week high at 40.66 USD - Investing.com
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Castle Biosciences stock hits 52-week high at 40.66 USD By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Castle Biosciences Inc. stock a top momentum playWeekly Investment Recap & Safe Swing Trade Setup Alerts - Улправда
Why Castle Biosciences Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Castle Biosciences Inc. stock positioned for digital transformationJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - Улправда
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares - MarketBeat
Why retail investors favor Castle Biosciences Inc. stockPortfolio Value Summary & Fast Momentum Entry Tips - Улправда
Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Castle Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - TradingView — Track All Markets
Can Castle Biosciences Inc. stock maintain operating marginsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is Castle Biosciences Inc. stock a buy before product launchesMarket Trend Review & Real-Time Volume Analysis - Улправда
Is Castle Biosciences Inc. stock trading at a premium valuationJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
COO Oelschlager Files To Sell 14,888 Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CEO reports stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Reveals Enhanced Predictive Method for Uveal Melanoma Outcomes - GuruFocus
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study - Investing.com
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination - Quiver Quantitative
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewswire
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Castle Biosciences Inc-Aktie (CSTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jan 06 '26 |
Sale |
40.10 |
1,339 |
53,689 |
29,513 |
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):